Abivax SA
PAR:ABVX
Abivax SA
Interest Expense
Abivax SA
Interest Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abivax SA
PAR:ABVX
|
Interest Expense
€18.8m
|
CAGR 3-Years
123%
|
CAGR 5-Years
81%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Interest Expense
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Interest Expense
€3.5m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
45%
|
|
|
Inventiva SA
PAR:IVA
|
Interest Expense
€16.7m
|
CAGR 3-Years
330%
|
CAGR 5-Years
301%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Interest Expense
$346k
|
CAGR 3-Years
46%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
Sensorion SA
PAR:ALSEN
|
Interest Expense
€314k
|
CAGR 3-Years
155%
|
CAGR 5-Years
81%
|
CAGR 10-Years
N/A
|
|
Abivax SA
Glance View
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
See Also
What is Abivax SA's Interest Expense?
Interest Expense
18.8m
EUR
Based on the financial report for Jun 30, 2025, Abivax SA's Interest Expense amounts to 18.8m EUR.
What is Abivax SA's Interest Expense growth rate?
Interest Expense CAGR 5Y
81%
Over the last year, the Interest Expense growth was 43%. The average annual Interest Expense growth rates for Abivax SA have been 123% over the past three years , 81% over the past five years .
